Acute MI: Public Health Issues

1
LIFE Major clinical end points in patients with
ISH
End point Losartan (n660) Atenolol (n666) Adjusted RR (95 CI) p
CV death/ stroke/MI 11.4 15.6 0.75 (0.56-1.01) 0.06
CV death 4.1 7.8 0.54 (0.34-0.87) 0.01
Stroke 4.8 8.4 0.60 (0.38-0.92) 0.02
MI 4.7 5.4 0.89 (0.55-1.44) 0.64
Total mortality 10.0 14.0 0.72 (0.53-1.00) 0.046
New-onset diabetes 5.8 9.0 0.62 (0.40-0.97) 0.04
RRrisk ratio
Kjeldsen SE et al. JAMA 20022881491-98.
2
LIFE Major clinical end points in patients
without ISH
End point Losartan (n660) Atenolol (n666) Adjusted RR (95 CI) p
CV death/ stroke/MI 11.0 12.3 0.90 (0.79-1.02) 0.11
CV death 4.5 4.6 0.99 (0.80-1.22) 0.90
Stroke 5.1 6.5 0.79 (0.66-0.95) 0.01
MI 4.2 3.9 1.12 (0.90-1.40) 0.30
Total mortality 8.0 8.6 0.95 (0.82-1.11) 0.51
New-onset diabetes 6.1 7.9 0.77 (0.64-0.92) 0.005
RRrisk ratio
Kjeldsen SE et al. JAMA 20022881491-98.